Site search

Clear filter
2965 results for '' found
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participant
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participant
/
Evaluation of Safety and Feasibility of the Tioga TMVR System for Treatment of Mitral Regurgitation (NCT06038838)
Evaluation of Safety and Feasibility of the Tioga TMVR System for Treatment of Mitral Regurgitation (NCT06038838)
/
Impact of Total Arterial Revascularisation in Coronary Artery Surgery on Angiographic and Clinical Outcomes (ACTRN12623000864628)
Impact of Total Arterial Revascularisation in Coronary Artery Surgery on Angiographic and Clinical Outcomes (ACTRN12623000864628)
/
A Multi-Centre Non-Inferiority Randomized Controlled Trial of STOPping Cardiac MEDications in Patients with Normalized Cancer Therapy Related Cardiac Dysfunction: The STOP-MED CTRCD Trial (NCT061
A Multi-Centre Non-Inferiority Randomized Controlled Trial of STOPping Cardiac MEDications in Patients with Normalized Cancer Therapy Related Cardiac Dysfunction: The STOP-MED CTRCD Trial (NCT061
/
The SMART-AF study (ACTRN12625000481471)
The SMART-AF study (ACTRN12625000481471)
/
The Alison Project: A randomised double-blind placebo controlled investigation of adjunctive memantine in the treatment of symptoms of complex trauma disorder (also known as borderline personalit
The Alison Project: A randomised double-blind placebo controlled investigation of adjunctive memantine in the treatment of symptoms of complex trauma disorder (also known as borderline personalit
/
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced M
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced M
/
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements (NCT05727176)
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements (NCT05727176)
/